Upcoming Earnings Reports: AMD, Pfizer, Disney, and More

Published 7 hours agoAMD

Upcoming Earnings Reports: AMD, Pfizer, Disney, and More

The week starting Monday, May 5, 2025, will be an eventful one for earnings reports, with several major companies set to reveal their financial results. AMD, a key player in the tech sector, is among the companies to watch as it prepares to release its earnings on Tuesday, May 6. Super Micro Computer will also share its quarterly performance on the same day.

Tuesday itself will see Pfizer, the pharmaceutical giant, report its earnings, bringing potential insights into the healthcare sector's ongoing performance. As the week unfolds, investors will get additional insights when The Walt Disney Company and Coinbase Global reveal their results on Wednesday, May 7. These reports should provide a glimpse into the entertainment and cryptocurrency markets.

Later in the week on Thursday, May 8, Plug Power and SoundHound AI are scheduled to disclose their financials, while Friday rounds out the week with Applied Digital Corporation and Future FinTech Group set to announce their earnings. This week's series of earnings calls offer a snapshot of various industries' health and are pivotal for investors aiming to gauge market conditions. Reuters highlighted the importance of staying updated with any changes to the schedule as company announcements may shift.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Palantir Hits Profit Milestone, While Buffett Prepares Berkshire Exit

Palantir Hits Profit Milestone, While Buffett Prepares Berkshire Exit

27 minutes agoPLTR

Palantir Technologies has posted its fifth consecutive quarter of GAAP profitability, reporting a net income of $93 million for the fourth quarter of 2023. The company's revenue saw a 20% year-over-year rise, reaching $608 million for the same period. Notably, its U.S. commercial sector experienced a robust revenue boost of 70% year-over-year, pulling in $131 million. Moreover, Palantir's adjusted free cash flow stood at $305 million, making up a 50% margin. Meanwhile, Warren Buffett has announced his retirement as CEO of Berkshire Hathaway by the end of 2025, after more than six decades of leadership. Greg Abel, who has been with the company since 1992 and was named as Buffett's successor in 2021, is set to take the reins. This transition brings mixed emotions among investors about the future of the $1.16 trillion company, with some expressing confidence in Abel's capabilities despite uncertain prospects without Buffett's legendary guidance. Palantir's stock saw a notable rise of 6.98%, closing at $124.28 on May 3, 2025. Similarly, Berkshire Hathaway's stock increased by 1.75%, closing at $809,350. These stock movements reflect investor reactions to Palantir's strong financial performance and the anticipated leadership transition at Berkshire Hathaway. As Reuters outlined, these developments continue to shape investor sentiment and market dynamics.

Coca-Cola vs PepsiCo: A Financial Showdown

Coca-Cola vs PepsiCo: A Financial Showdown

42 minutes agoKO

PepsiCo and Coca-Cola are often compared when it comes to potential stock investments, offering investors unique qualities to consider. In recent years, PepsiCo has shown more resilient revenue growth, with a 4.80% increase in 2020, contrasting with Coca-Cola's 11.40% revenue decline during the same period. Looking ahead, PepsiCo's earnings per share (EPS) are expected to rise by 7% in 2024 and 5% in 2025, reaching $8.59 per share. Coca-Cola's EPS, on the other hand, is projected to grow by 6% in 2024 and 3% in 2025, hitting $2.96 per share. Dividend enthusiasts may find PepsiCo's offerings particularly appealing. The company currently boasts a higher dividend yield of 3.71% compared to Coca-Cola's 2.71%. Additionally, over the past five years, PepsiCo has increased its dividend by an average of 6.44% annually, while Coca-Cola's average dividend growth stands at 3.70%. Valuation metrics tell a different story, with Coca-Cola featuring a P/E ratio of 24.73—and a forward P/E of 20.0x, which is below its long-term average—while PepsiCo's P/E ratio sits at 32 times, alongside a forward P/E of 35.2. Notably, PepsiCo's price-to-sales (P/S) ratio is 2.49, notably lower than Coca-Cola's 5.14, suggesting a difference in perceived value relative to sales. In terms of business strategies, PepsiCo's diverse product lineup, which includes popular snack brands like Frito-Lay and Quaker, positions it for broad growth opportunities. Meanwhile, Coca-Cola continues to leverage its market-leading beverage status and adapt to consumer shifts through ventures into alcoholic and plant-based products. Reuters reported that while both companies hold strong positions in their respective markets, PepsiCo’s diversified approach and robust dividend may present a more attractive option for growth and income-seeking investors. Coca-Cola, however, remains a strong contender with its consistent dividend performance and adaptability in product offerings.

Alphabet Exceeds Earnings Expectations, Announces First Dividend

Alphabet Exceeds Earnings Expectations, Announces First Dividend

57 minutes agoGOOGL

Alphabet Inc. has recently delivered robust financial results and revealed plans to return value to shareholders, bolstering its position as a potential growth stock. The search giant reported a 15% rise in revenue to $80.54 billion for the first quarter, beating analyst forecasts of $78.59 billion. Net income surged by an impressive 57.2% to $23.66 billion, translating to $1.89 per share and exceeding expectations of $1.51 per share. In particular, the strong performance was driven by a 13% increase in advertising revenue, which reached $61.7 billion thanks to Google Search and YouTube's solid results. Additionally, Google Cloud saw a 28% expansion in revenue, largely due to growing demand for AI-related services. Reuters highlighted that these advances in advertising and cloud services have effectively aided Alphabet in maintaining its competitive edge in the tech sector. Alphabet has taken steps to reward its shareholders by declaring a $0.20 cash dividend per share, marking the company's first-ever dividend payout. Furthermore, it has authorized a substantial $70 billion stock repurchase program, signaling confidence in its continued financial health. The company remains deeply invested in artificial intelligence, which enhances its suite of products, including AI Overviews that now serve 1.5 billion users monthly.

Gilead Settles Kickback Lawsuit, While CVS and Sanofi Make Strategic Shifts

Gilead Settles Kickback Lawsuit, While CVS and Sanofi Make Strategic Shifts

1 hours agoGILD

Gilead Sciences has agreed to pay $202 million to resolve a lawsuit concerning accusations of providing kickbacks to doctors for promoting its HIV medications. The U.S. Attorney's Office in Manhattan revealed that from 2011 to 2017, Gilead violated federal laws by offering $23.7 million in incentives such as speaker fees, lavish meals, and trips, to encourage doctors to prescribe drugs like Biktarvy and Stribild. These actions allegedly led to fraudulent claims to Medicare and Medicaid. Gilead mentioned the settlement as a means to avoid further litigation costs, with reserved funds already in place. CVS Health has revised its profit forecast for 2025 upwards, after rebounding from significant financial setbacks. The updated adjusted profit forecast now stands at $6.00–$6.20 per share, up from $5.75–$6.00, sending its stock up by 8.5% in premarket trading. Previously, CVS shares fell over 40% due to underperformance in specific segments. Additionally, the company reported a first-quarter adjusted profit of $2.25 per share, exceeding the expected $1.70. Glenview Capital Management, an activist hedge fund, has also secured four new board seats, expanding the CVS board to 16 members as part of an effort to stabilize leadership and finances. Sanofi is planning to modify its discount policy under the 340B program, targeting U.S. hospitals that care for low-income and uninsured patients. The change, set for implementation early next year, will mean hospitals must submit pharmacy and medical claims to access discounts. This adjustment in policy comes amid lawsuits from other pharmaceutical companies, such as Eli Lilly and Johnson & Johnson, challenging similar changes related to the 340B program. These strategic shifts from Gilead, CVS, and Sanofi highlight significant moves in the healthcare sector, impacting how drugs are marketed, profits are forecasted, and discounts are managed.